Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK to highlight scientific research in ovarian and endometrial cancer at SGO 2021 Annual Meeting on Women’s Cancer
This research builds on the body of evidence supporting poly (ADP-ribose) polymerase (PARP) inhibitor use for maintenance treatment.
-
GSK starts the first phase 3 study with a long-acting anti-IL-5 treatment for patients with severe asthma
GSK '294 is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Medicago/GSK announce Ph 3 trial start of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant.
-
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
-
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.
-
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks
Long-term efficacy and safety data from phase IIIb ATLAS-2M study reinforce therapeutic potential of long-acting cabotegravir & rilpivirine
-
GSK makes landmark pricing agreement for rotavirus vaccine, Rotarix, for use with children living in humanitarian crises
GSK has committed to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism.
-
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
The independent DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.
-
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
16 sponsored abstracts from our diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options will be presented
-
GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19
GSK today announce results from the phase 2 proof of concept OSCAR study with otilimab, an investigational anti-GM-CSF monoclonal antibody.
-
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders, announced today the submission of a sNDA to the US FDA
-
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.
-
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
Companies to combine expertise in immunology and infectious diseases to accelerate development of promising new therapeutics for influenza.
-
GSK announces gender and diversity aspirational targets to increase representation at senior levels
Aspirational targets to increase ethnically diverse senior leadership in the US and UK.
-
GSK announces over $1M for local nonprofits to increase equity in STEM education and careers; Grants include funding for online science during pandemic
Our 10-year commitment to increase the number of women and Black and Latinx Philadelphia students entering careers in STEM
-
GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER
Strong growth of new and specialty products; on track to deliver two exciting new companies
-
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
-
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases.
-
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.
-
GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases
Ranking reflects GSK leadership through access to its medicines and vaccines for people around the world.
